Loading...
Loading...
IBRX| Name | Value |
|---|---|
| Revenues | 0.4M |
| Cost of Revenue | 6.3M |
| Gross Profit | -5.9M |
| Operating Expense | 111.9M |
| Operating I/L | -111.6M |
| Other Income/Expense | -5.0M |
| Interest Income | 0.3M |
| Pretax | -116.6M |
| Income Tax Expense | 34.6M |
| Net Income/Loss | -151.2M |
ImmunityBio, Inc. is a clinical-stage biotechnology company specializing in developing immunotherapy and cell therapy platforms for treating cancers and infectious diseases. The company's product portfolio includes antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. ImmunityBio also focuses on developing therapeutic agents for Phase II or III clinical trials targeting liquid and solid tumors such as bladder, pancreatic, and lung cancers, as well as infectious diseases like SARS-CoV-2 and HIV.
